FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1919210083> ?p ?o ?g. }

• W1919210083 abstract "Phosphatidylserine-containing liposomes (PSL) have been shown to reduce inflammation in experimental models of acute arthritis, by mimicking the apoptotic process. The aim of this study was to evaluate the effect of pegylated PSL (PEG-PSL) on chronic inflammation of collagen induced arthritis (CIA) in DBA/1J mice. CIA was induced in 24 DBA/1J mice (n = 6/group), which were divided into control (0.9 % saline) or treated with PEG-PSL (5, 10 and 15 mg/kg/day, subcutaneously for 20 days). Clinical score, limb histology and measurement of cytokines in knee joints of animals by ELISA and cytometric bead array (CBA) were evaluated. The in vitro study employed macrophage cultures stimulated with 100 ng/ml of LPS plus 10 ng/ml of PMA and treated with 100 μM PEG-PSL. Resolution of the disease in vivo and the inflammatory process in vitro were not observed. PEG-PSL, in doses of 10 and 15 mg/kg, were not shown to reduce the score of the disease in animals, whereas with the dose of 5 mg/kg, the animals did not show the advanced stage of the disease when compared to the controls. The PEG- PSL 5, 10 and 15 mg/kg treatment groups did not show significant reduction of TNF-α, IL-1β, IL-6, IL-2 and IFN-γ when compared to the controls. Disease incidence and animal weights were not affected by treatment. Regarding the paw histology, PEG-PSL did not yield any reductions in the infiltrating mononuclear, synovial hyperplasia, extension of pannus formation, synovial fibrosis, erosion of cartilage, bone erosion or cartilage degradation. The concentration of 100 μM of PEG-PSL has not been shown to reduce inflammation induced by LPS/PMA in the in vitro study. Treated groups did not show any reduction in inflammatory cytokines in the knee joints of animals affected by the disease compared to the control, although there were higher concentrations of TGF-β1 in all experimental groups. The experimental model showed an expression of severe arthritis after the booster. TGF-β1 as well other pro inflammatory cytokines were presented in high concentrations in all groups. PEG-PSL had no impact on the clinical score, the histopathology from tibial-tarsal joints or the production of cytokines in the knee joints. Other alternatives such as dosage, route of administration, and as an adjunct to a drug already on the market, should be evaluated to support the use of PEG-PSL as a new therapeutic tool in inflammatory diseases." @default.
• W1919210083 created "2016-06-24" @default.
• W1919210083 creator A5003985393 @default.
• W1919210083 creator A5017740190 @default.
• W1919210083 creator A5021771730 @default.
• W1919210083 creator A5058673417 @default.
• W1919210083 creator A5061273554 @default.
• W1919210083 creator A5081232050 @default.
• W1919210083 creator A5082221558 @default.
• W1919210083 creator A5082508212 @default.
• W1919210083 creator A5086510776 @default.
• W1919210083 creator A5089576020 @default.
• W1919210083 date "2015-09-22" @default.
• W1919210083 modified "2023-10-17" @default.
• W1919210083 title "Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis" @default.
• W1919210083 cites W102264952 @default.
• W1919210083 cites W1506880296 @default.
• W1919210083 cites W1763685036 @default.
• W1919210083 cites W1940692702 @default.
• W1919210083 cites W1971342115 @default.
• W1919210083 cites W1976912963 @default.
• W1919210083 cites W1978224572 @default.
• W1919210083 cites W1980167867 @default.
• W1919210083 cites W1980792888 @default.
• W1919210083 cites W1984761779 @default.
• W1919210083 cites W2005083315 @default.
• W1919210083 cites W2036999916 @default.
• W1919210083 cites W2040176672 @default.
• W1919210083 cites W2041019072 @default.
• W1919210083 cites W2045539935 @default.
• W1919210083 cites W2055796980 @default.
• W1919210083 cites W2061844961 @default.
• W1919210083 cites W2081834018 @default.
• W1919210083 cites W2083221557 @default.
• W1919210083 cites W2088005735 @default.
• W1919210083 cites W2091483395 @default.
• W1919210083 cites W2093656894 @default.
• W1919210083 cites W2094156235 @default.
• W1919210083 cites W2103645643 @default.
• W1919210083 cites W2121892405 @default.
• W1919210083 cites W2125846694 @default.
• W1919210083 cites W2131523916 @default.
• W1919210083 cites W2146607274 @default.
• W1919210083 cites W2151181789 @default.
• W1919210083 cites W2160021744 @default.
• W1919210083 cites W4235300003 @default.
• W1919210083 doi "https://doi.org/10.1186/s40360-015-0022-0" @default.
• W1919210083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4578330" @default.
• W1919210083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26392267" @default.
• W1919210083 hasPublicationYear "2015" @default.
• W1919210083 type Work @default.
• W1919210083 sameAs 1919210083 @default.
• W1919210083 citedByCount "10" @default.
• W1919210083 countsByYear W19192100832017 @default.
• W1919210083 countsByYear W19192100832018 @default.
• W1919210083 countsByYear W19192100832019 @default.
• W1919210083 countsByYear W19192100832020 @default.
• W1919210083 countsByYear W19192100832021 @default.
• W1919210083 countsByYear W19192100832022 @default.
• W1919210083 crossrefType "journal-article" @default.
• W1919210083 hasAuthorship W1919210083A5003985393 @default.
• W1919210083 hasAuthorship W1919210083A5017740190 @default.
• W1919210083 hasAuthorship W1919210083A5021771730 @default.
• W1919210083 hasAuthorship W1919210083A5058673417 @default.
• W1919210083 hasAuthorship W1919210083A5061273554 @default.
• W1919210083 hasAuthorship W1919210083A5081232050 @default.
• W1919210083 hasAuthorship W1919210083A5082221558 @default.
• W1919210083 hasAuthorship W1919210083A5082508212 @default.
• W1919210083 hasAuthorship W1919210083A5086510776 @default.
• W1919210083 hasAuthorship W1919210083A5089576020 @default.
• W1919210083 hasBestOaLocation W19192100831 @default.
• W1919210083 hasConcept C10464949 @default.
• W1919210083 hasConcept C126322002 @default.
• W1919210083 hasConcept C142724271 @default.
• W1919210083 hasConcept C150903083 @default.
• W1919210083 hasConcept C203014093 @default.
• W1919210083 hasConcept C204787440 @default.
• W1919210083 hasConcept C207001950 @default.
• W1919210083 hasConcept C2524010 @default.
• W1919210083 hasConcept C2776164576 @default.
• W1919210083 hasConcept C2776268809 @default.
• W1919210083 hasConcept C2776914184 @default.
• W1919210083 hasConcept C2777077863 @default.
• W1919210083 hasConcept C33923547 @default.
• W1919210083 hasConcept C57742111 @default.
• W1919210083 hasConcept C71924100 @default.
• W1919210083 hasConcept C86803240 @default.
• W1919210083 hasConcept C98274493 @default.
• W1919210083 hasConceptScore W1919210083C10464949 @default.
• W1919210083 hasConceptScore W1919210083C126322002 @default.
• W1919210083 hasConceptScore W1919210083C142724271 @default.
• W1919210083 hasConceptScore W1919210083C150903083 @default.
• W1919210083 hasConceptScore W1919210083C203014093 @default.
• W1919210083 hasConceptScore W1919210083C204787440 @default.
• W1919210083 hasConceptScore W1919210083C207001950 @default.
• W1919210083 hasConceptScore W1919210083C2524010 @default.
• W1919210083 hasConceptScore W1919210083C2776164576 @default.
• W1919210083 hasConceptScore W1919210083C2776268809 @default.
• W1919210083 hasConceptScore W1919210083C2776914184 @default.
• W1919210083 hasConceptScore W1919210083C2777077863 @default.

• next